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Combined LRRK2 mutation, aging 
and chronic low dose oral rotenone 
as a model of Parkinson’s disease
Hui-Fang Liu1,*, Philip Wing-Lok Ho1,*, Gideon Chi-Ting Leung1, Colin Siu-Chi Lam1, 
Shirley Yin-Yu Pang1, Lingfei Li1, Michelle Hiu-Wai Kung1, David Boyer Ramsden2 &  
Shu-Leong Ho1
Aging, genetics and environmental toxicity are important etiological factors in Parkinson’s disease (PD). 
However, its pathogenesis remains unclear. A major obstacle is the lack of an appropriate experimental 
model which incorporates genetic susceptibility, aging and prolonged environmental toxicity. Here, we 
explored the interplay amongst these factors using mutant LRRK2R1441G (leucine-rich-repeat-kinase-2) 
knockin mice. We found that mutant primary cortical and mesencephalic dopaminergic neurons were 
more susceptible to rotenone-induced ATP deficiency and cell death. Compared with wild-type controls, 
striatal synaptosomes isolated from young mutant mice exhibited significantly lower dopamine uptake 
after rotenone toxicity, due to reduced striatal synaptosomal mitochondria and synaptic vesicular 
proton pump protein (V-ATPase H) levels. Mutant mice developed greater locomotor deficits in open-
field tests than wild-type mice following low oral rotenone doses given twice weekly over 50 weeks 
(half their lifespan). The increased locomotor deficit was associated with specific reduction in striatal 
mitochondrial Complex-I (NDUFS4) in rotenone-treated mutant but not in similarly treated wild-type 
mice. Our unique experimental model which incorporates genetic effect, natural aging and prolonged 
oral environmental toxicity administered to mutant knockin LRRK2 mice over half their life span, with 
observable and measurable phenotype, is invaluable in further studies of the pathogenic process and 
therapeutics of PD.
Parkinson’s disease (PD) is a common neurodegenerative disease characterized by loss of dopaminergic neu-
rons in substantia nigra par compacta (SNpc) and dopamine (DA) depletion in the striatum. Current evidence 
indicates that its pathogenesis involves a complex interaction of aging, genetic susceptibility, and environmental 
factors, especially in sporadic PD1. Its incidence and prevalence are rare before the age of 50 years and increase 
substantially with aging2. At least 12 genes have been linked to familial PD3. Furthermore, whole genome studies 
showed genetic risks in sporadic PD cases4. Among these genetic risks, those of LRRK2 mutations are the most 
common, being found in up to 2% of sporadic cases5,6. The LRRK2R1441G mutation, which is at the same location 
as the LRRK2R1441C mutation, is located in the ROC (Ras of complex proteins) domain of the LRRK2 gene7–10, and 
is the most common cause of familial PD in the Basque region of Spain11. LRRK2-associated PD demonstrates 
indistinguishable clinical features from typical idiopathic cases, suggesting that they may share similar pathogenic 
mechanisms12. Hence, LRRK2 mutations are appropriate genetic models in PD.
Various therapeutic strategies have failed to modify the disease processes in PD13. One important reason is the 
lack of an appropriate experimental model which reflects the pathogenic processes in human sporadic PD14–16. 
Epidemiological studies have strongly suggested that environmental risk factors are involved1,17,18. Plantation and 
farm workers exposed to chronic pesticide use were found to be more likely to develop PD19,20. Indeed, a naturally 
occurring pesticide, rotenone, is used as a specific mitochondrial Complex-I inhibitor in experimental models 
of PD16,21,22. However, most existing toxin-based models utilize high doses of toxins administered over a short 
period14,15,23,24, which does not occur in most cases of PD in human. We hypothesize that the majority of cases 
of sporadic PD is a result of a combination of genetic susceptibility, environmental toxin exposure and aging in 
various proportions. This combination of factors has not been explored previously in an animal model. Hence, 
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developing an appropriate experimental animal model involving these etiological factors is crucial to explore the 
early pathological processes with clinical relevance and future development of disease-modifying therapies25,26. 
Thus, the aim of this study is to characterize the abnormalities in a knockin (KI) mutant mouse model that 
incorporates these three most important risk factors: genetic susceptibility (LRRK2 KI mutation), environmental 
toxin (rotenone), and aging. We studied the effects of the KI mutation and toxin exposure in in vitro and ex vivo 
samples from prenatal and young animals, respectively. Age was then introduced as a third factor in the in vivo 
experiments.
Results
Mutant knockin cortical neurons were much more susceptible to rotenone-induced cell death 
and ATP depletion. Primary cortical neuronal cultures from LRRK2R1441G KI mice had significantly lower 
cell viability as quantified by MTT assay and cellular ATP levels compared with wild-type (WT) after rotenone 
exposure for 6 hr (Fig. 1c and d). Significant differences between WT and mutant cortical neurons were observed 
in cell viability at 25 and 50 nM rotenone (N = 3; p < 0.05), and in ATP levels at 10 and 25 nM (N = 3; p < 0.01) 
rotenone. There were no significant differences in cell viability and cellular ATP levels between untreated WT and 
mutant cortical neurons (Fig. 1b).
Mutant knockin mesencephalic dopaminergic (DA) neurons were more susceptible to 
rotenone-induced toxicity. Mesencephalic DA neurons from E14.5 mouse embryos were treated with 
vehicle or rotenone (5 and 10 nM) for 48 hr. The whole culture was PFA-fixed and stained with antibody against 
tyrosine hydroxylase (TH; DA neuron marker). Total DA cell survival before and after treatment were assessed 
by manual counting of total TH+ cell in the whole culture by two blinded independent assessors under light 
microscopy (Fig. 2a). WT primary DA neurons showed similar levels of cell survival at 5 nM, and 78.5 ± 9.7% at 
10 nM rotenone compared with its corresponding untreated WT control group after 48 hr (Fig. 2b). In contrast, 
Figure 1. Cell viability and ATP levels of LRRK2R1441G mutant mouse primary cortical neurons after 
rotenone exposure. Primary cortical cultures were prepared from E14.5 mutant LRRK2R1441G and WT 
mice, and treated with 10, 25, 50, 100 nM rotenone, or vehicle (DMSO; 0.01% in culture) for 6 hr. (a) No 
morphological differences were observed between WT and mutant cortical neurons (DIV7) under normal 
untreated condition. Scale = 100 μ m. (b) There were no significant differences in basal cellular ATP levels 
between untreated WT (solid lines) and mutant (dotted lines) cortical neurons. (c) Mutant cortical neurons were 
more susceptible to rotenone in a dose-dependent manner in MTT assay, and (d) ATP depletion, as compared 
to rotenone-treated WT group. Results are expressed as percentages relative to its corresponding vehicle-treated 
controls. Data represents mean ± standard error of mean (SEM) from three independent experiments (N = 3). 
Statistical significance between groups was analyzed by unpaired t-test. *P < 0.05; **P < 0.01.
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the relative survival of mutant DA neurons had reduced to 78.5 ± 2.5% at 5 nM and 49.0 ± 0.07% at 10 nM rote-
none compared to its untreated mutant control. There were significant differences in relative cell survival between 
WT and mutant DA neurons in both the 5 nM and 10 nM rotenone treatment groups (N ≧ 3; p < 0.001). The 
lower survival of mutant DA neurons following rotenone exposure is compatible with the reduced cell viability 
and greater ATP depletion observed in mutant cortical neurons following rotenone exposure, compared to WT.
Increased vulnerability to rotenone in mutant striatal synaptosomes was associated with lower 
DA uptake, and reduced mitochondria and vesicular V-ATPase H levels in nerve terminals. DA 
uptake in striatal presynaptic terminals is known to be reduced in PD27,28. Therefore, we investigated the effects of 
rotenone on synaptosomal radiolabeled DA ([3H]-DA) uptake. Synaptosomes purified from striatum of WT and 
mutant 3-month old mice were exposed to 100 nM and 1000 nM rotenone and radiolabeled [3H]-DA uptake into 
the synaptosomes was quantified. Following rotenone exposure, [3H]-DA uptake into striatal synaptosomes was 
significantly lower in isolates from mutant mice compared with the results using WT isolate at 100 nM rotenone 
(WT: 7045 ± 583 cpm; mutant: 5311 ± 405 cpm; N = 11; P < 0.05) but the difference did not reach significance at 
1000 nM rotenone (WT: 3034 ± 290 cpm; mutant: 2048 ± 500 cpm; N = 7) (Fig. 3a). The lack of significant differ-
ence at 1000 nM rotenone may be due to excessive toxicity, as reflected by the great reduction in [3H]-DA uptake 
even in WT.
To understand why mutant striatal synaptosomes exhibited lower DA uptake than WT under rotenone tox-
icity, we examined for differences in expression of CoxIV (marker of the amount of mitochondria.), V-ATPase 
H (synaptic vesicle proton pump protein), and SV2a (a synaptic vesicle marker protein), which were normalized 
by synaptophysin levels (a presynaptic nerve terminal marker protein). Immunoblotting results showed similar 
levels of SV2a indicating similar amounts of vesicles in striatal synaptosomes isolated from WT and mutant mice. 
However, CoxIV and V-ATPase H expression levels were significantly lower in striatal synaptosomes from mutant 
mice indicating lower amounts of mitochondria and synaptic vesicle proton pump protein respectively in mutant 
presynaptic nerve terminals compared with WT (Fig. 3b). These results indicate that the susceptibility to rote-
none, as reflected by reduced DA uptake, is due to the effects of reduced synaptosomal mitochondria and vesicle 
proton pump protein levels in striatal presynaptic nerve terminals of the mutant mice.
Rotenone-treated mutant LRRK2R1441G knockin mice had greater locomotor deficits compared 
with similarly treated wild-type mice as they aged. We then explored the combined effects of aging, 
LRRK2 knockin mutation and chronic rotenone toxicity in four sets of animals – WT vehicle-treated, WT 
rotenone-treated; mutant vehicle -treated; mutant rotenone-treated. Aging is inherent in this treatment regime 
because it spans approximately half the normal lifespan of the mice. Rotenone (5 mg/kg) was administered to 
30-week old mice via bolus oral gavage twice a week for a further 50 weeks (Fig. 4a). To avoid variations in the 
amount of toxin exposure between each dose and individual mice, we ensured that each rotenone treatment 
administered via oral gavage was identical. Apart from the genotype and rotenone treatment, the other factors 
such as food, drink and environment were kept the same amongst all treatment groups of mice. The mice were 
assessed for locomotor activity (distance moved, movement duration and rearing frequency) every 5 weeks over 
11 time points using open-field tests, which were recorded at similar times for 1 hr.
We analyzed the combined effects of LRRK2 mutation, rotenone treatment and aging on the mice using 
the cumulative locomotor parameters over 50 weeks by three-way ANOVA (Supplementary Tables S4–6). The 
combination of genotype with aging had no significant effect on all three locomotor parameters. However, the 
Figure 2. Cell viability of LRRK2R1441G mutant mouse primary dopaminergic (DA) neurons after rotenone 
exposure. Primary mesencephalic DA neuronal cultures (DIV7) from mutant and WT mouse embryos 
(E14.5) were treated with 5 or 10 nM rotenone (Rot), or vehicle (Veh: DMSO; 0.01% in culture) for 48 hr. 
(a) Immunostaining of DA neurons using anti-tyrosine hydroxylase (TH) antibody after treated with 5 nM 
rotenone. Total number of TH-positive cells in culture was counted by two blinded observers independently 
under light microscope. (b) Relative survival of mutant DA neurons was significantly lower after exposure to 
rotenone than similarly treated WT groups. Data represents mean ± standard error of mean (SEM) from three 
independent experiments (N ≥ 3). Statistical significance between groups was analyzed by one-way ANOVA 
and Tukey post-hoc test, ***P < 0.001.
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combination of genotype and rotenone treatment had a significant effect on distance moved (df = 1, F = 7.856, 
p < 0.01), movement duration (df = 1, F = 6.871, p < 0.01) and rearing frequency (df = 1, F = 3.78, p < 0.05), with 
rotenone-treated mutant mice having the lowest values on all three parameters. Interestingly, mutant mice treated 
with vehicle appeared more active than similarly treated WT mice with distance moved and rearing frequency 
although the differences were not significant (Fig. 4b and d). Not surprisingly, both WT and mutant mice treated 
with rotenone had greater deficits in all three parameters compared to those treated with vehicle. However, there 
was a significantly greater decrease in these parameters in mutant mice treated with rotenone compared with 
similarly treated WT mice (distance moved - WT: ↓ 16.7%, mutant: ↓ 36.6%; movement duration - WT: ↓ 16.8%, 
mutant: ↓ 35.5%; rearing frequency - WT: ↓ 36.0%, mutant: ↓ 54.3%). The parameters shown in Fig. 4b were tested 
against a linear fit (y = α x + β , where y = cumulative parameter and x = time (Fig. 4c). Unlike the WT mice which 
had similar gradients between rotenone- and vehicle-treatment, the gradients for all 3 locomotor parameters over 
50 weeks for rotenone-treated mutant mice were significantly less than vehicle-treated mutant mice (Fig. 4c and 
d). These findings indicate that the LRRK2 mutation conferred a significant vulnerability to chronic rotenone 
toxicity in inducing locomotor deficits as the mice aged. Similar analyses on these locomotor parameters based on 
individual data point over 50 weeks of rotenone gave similar statistical results (Supplementary Fig. 1; Table S1–3)
Rotenone-treated mutant mice had similar levels of tyrosine hydroxylase (TH) expression and 
apoptosis compared with similarly treated WT mice. Dopaminergic neurons and neurites on the 
substantia nigra pars compacta (SNpc) and striatum from vehicle- and rotenone-treated mice were examined 
following chronic rotenone treatment. Immunohistochemistry studies revealed similar TH expression in SNpc 
and striatum in all four groups of mice (Fig. 5). There were no observable differences in the gross structure of the 
dopaminergic neurons and neurites from WT compared with mutant mice, irrespective of whether the mice were 
treated with rotenone or not. Furthermore, similar levels of TH expression were found in total striatal lysate from 
mutant and WT mice, with or without rotenone treatment (Fig. 6).
TUNEL staining was performed in striatum, SNpc, and cortex to assess the levels of apoptosis after rotenone 
treatment. Compared with vehicle-treated groups, rotenone-induced apoptosis in both mutant and WT mice was 
shown by markedly increased TUNEL-positive cells in these three brain regions (Figs 7a–c and 8a) as analyzed 
using ImageJ software (Fig. 7d). There were no significant differences in levels of apoptosis between similarly 
treated mutant and WT mice (Figs 7d and 8b). Although the rotenone dosage was low and did not cause sig-
nificant DA cell loss, it was sufficiently effective to induce nigro-striatal and cortical apoptosis after 50 weeks 
of exposure which was associated with greater functional deficit in mutant striatal synaptosomal DA uptake as 
described above.
Rotenone-treated mutant mice had significantly lower mitochondrial Complex-I subunit 
(NDUFS4) levels in striatum than similarly treated WT mice. As rotenone is a mitochondrial 
toxin and a specific Complex-I inhibitor, we examined for more subtle differences in striatal mitochondria after 
Figure 3. Effects of rotenone on synaptosomal [3H]-DA uptake, and changes in protein levels of CoxIV, 
V-ATPase H and SV2a in 3-month-old mouse striatal synaptosomes. (a) Greater reduction in LRRK2R1441G 
mutant synaptosomal [3H]-DA uptake at 100 nM rotenone as compared to similarly treated WT (WT: 
7045 ± 583 cpm; mutant: 5311 ± 405 cpm). Data represents mean ± standard error of mean (SEM) from at least 
seven independent experiments. (b) Protein expression levels of CoxIV, V-ATPase H and SV2a in 3-month-
old mouse striatal synaptosomes. CoxIV and V-ATPase H levels in total striatal synaptosomal lysates were 
significantly lower in mutant mice compared to WT controls (N = 6). Statistical significance between groups 
was analyzed using Student’s unpaired t-test, *p < 0.05.
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rotenone treatment. In total striatal lysate, CoxIV expression was similar between mutant and WT mice, with 
or without rotenone treatment. However, there was a significant reduction in mitochondrial Complex-I subunit 
(NDUFS4) levels in striatum from rotenone-treated mutant mice, which was not observed in rotenone-treated 
WT mice (N = 4; p < 0.01) (Fig. 6). In comparison, vehicle-treated WT and mutant mice had similar striatal 
NDUFS4 levels. These results indicated that the vulnerability conferred by LRRK2 mutation to chronic environ-
mental toxic exposure in the form of rotenone as the mice aged was associated with reduced striatal mitochon-
drial Complex-I levels.
Figure 4. Greater reduction in locomotor activity in LRRK2R1441G mutant mice after 50 weeks of low dose 
oral administration of rotenone (5 mg/kg). (a) Mice were treated orally with 5 mg/kg rotenone or vehicle 
(4% carboxymethylcellulose) twice per week for 50 weeks, and their locomotor activity was assessed in every 
five weeks. (b) Open-field test locomotor parameters were presented in cumulative parameter-time graphs. 
Each data point is expressed as mean ± standard error of mean (SEM). Three-way ANOVA showed that the 
combination of LRRK2R1441G mutation and rotenone treatment had a significant effect on distance moved 
(p < 0.01), movement duration (p < 0.01) and rearing frequency (p < 0.05), with rotenone-treated mutant mice 
having the lowest values on all three parameters. There was a significantly greater decrease in these parameters 
in mutant mice treated with rotenone compared with similarly treated WT mice (Supplementary Table S1–3). 
(c,d) Gradients of cumulative distance moved, movement duration and rearing frequency of each treatment 
group over 50 weeks of rotenone administration. Statistical significance between groups was analyzed using 
Student’s unpaired t-test, *p < 0.05, **P < 0.01. (Vehicle-treated WT control group, N = 8; Vehicle-treated 
mutant group, N = 6; Rotenone-treated WT group, N = 7; Rotenone-treated mutant group, N = 8).
www.nature.com/scientificreports/
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Discussion
Aging is well-established risk factor in PD29,30. Mitochondria dysfunction is also associated with aging with more 
accumulated mutations31–33. However, aging and chronic exposure to environmental toxins by themselves are not 
the only risk factors to developing PD. There are very few population clusters of PD except in rare familial cases34–36. 
There are also very few conjugal cases of PD even in long lasting marriages35,36. Furthermore, monozygotic twins 
are more likely to develop PD than dizygotic twins, and the inheritance effect was more evident in younger onset 
twin-sets37. Epidemiological studies also showed that inheritance confers an increased risk of developing PD, with 
first degree relatives of PD patients having a higher risk of PD than second or third degree relatives38,39, suggesting 
a role of genetic susceptibility in the development of PD. However, inheritance alone is unlikely to be a significant 
risk factor to sporadic PD, compatible with the results obtained from our experimental model here and the exist-
ence of non-symptomatic mutant LRRK2 human carriers even in old age40,41.
PD associated with LRRK2 mutations has mostly indistinguishable features from sporadic PD, both of which 
tend to occur in older patients5,42. Transgenic and knockout animal models including those with mutated LRRK2 
have been reported with abnormal phenotype associated with PD43–46. However, mutant LRRK2 knockin mice 
may more closely mimic PD because human mutant LRRK2 carriers have similar LRRK2 expression levels as 
those without the mutation47–49. Although most mutant LRRK2 human carriers are heterozygous, we used the 
Figure 5. Immunohistochemistry of tyrosine hydroxylase (TH) in the substantia nigra pars compacta (SNpc) and 
striatum from WT and LRRK2R1441G mutant mice after 50-week oral rotenone administration. Scale = 150 μ m (a) and 
200 μ m (b). There was no significant difference in TH-positive cell numbers in SNpc and striatal TH staining density 
between WT and mutant mice rotenone treatment (Student’s unpaired t-test). Data represents mean ± standard error 
of mean (SEM) from three independent experiments (N = 3).
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homozygous knockin mouse model to accentuate the genetic risk. In our mutant mice, the R1441G mutated 
Lrrk2 gene is located at the intended site in the Lrrk2 locus, thus achieving biological regulation and expression 
patterns and levels as in WT50–52. This is in contrast to a transgenic R1441G mouse model which expressed higher 
LRRK2 protein level by about five to tenfold as compared to the endogenous protein in normal WT mice53. 
Despite an earlier or more robust phenotype observed, these transgenic models have their limitations that the 
expression pattern may not be an accurate representation of the situation in human PD23,54. Similarly, knockout 
mouse is genetically modified by inactivating, deleting or replacing the target gene. Whilst the knockout model is 
useful to explore gene function, there are no published reports of humans without LRRK2 expression.
There are three LRRK2 mutant knockin mouse models previously reported based on the R1441C50, R1441G51 
and G2019S52 mutations. Homozygous mutant LRRK2 mice were used to accentuate the genetic risk. Despite 
their homozygosity, our LRRK2 mutant mice had no significant loss of dopamine neurons and locomotor defi-
cits even in old age. However, there are increasing reports that these mutant LRRK2 knockin mice exhibit subtle 
abnormalities such as abnormal mitochondrial morphology52, different behavioral characteristics after amphet-
amine exposure50 and increased susceptibility to synaptic dysfunction even in young 3-month-old mice51. These 
findings are compatible with similar observation in humans where non-symptomatic mutant LRRK2 carriers 
showed abnormal DAT-SPECT55,56 and increased SN hyperechogenicity57,58.
Mitochondrial Complex-I activity is reduced in PD brain59,60, although it is unclear whether it is a primary or 
secondary event. We used rotenone to mimic an environmental stress to mitochondria because it exists naturally 
as a common organic pesticide produced by the pachyrhizus erosus plant61. We used different concentrations 
and times of exposure to rotenone between in vitro primary cell culture experiments and ex vivo striatal synap-
tosomal DA uptake assays is because these experiments have different aims involving different biological sam-
ples. Different biological samples have different susceptibilities to rotenone. In Fig. 1, we used primary cortical 
neuronal cultures from mouse embryos whereas in Fig. 3, we used striatal synaptosomes freshly isolated from 
young adult mice. In Fig. 1, we tested for neuronal cell viability and ATP depletion after rotenone toxicity (i.e. 
0–100 nM) over 6 hours. In Fig. 3, we tested for DA uptake into striatal synaptosomes after 5 min of rotenone 
exposure (i.e. 100–1000 nM). Rotenone is a specific mitochondrial Complex-I inhibitor which irreversibly blocks 
mitochondrial ATP synthesis62. Although high doses of rotenone (e.g. 30 to 100 mg/kg) given repetitively over 
a short period (e.g. daily for 1 to 2 months) had resulted in relatively acute development of parkinsonian motor 
deficits and permanent damage in nigrostriatal dopaminergic neurons in various animal models63,64, they do not 
reflect the situation in sporadic PD which usually takes years to progress in human. Moreover, the toxicity caused 
by high doses of rotenone given within a short period may mask the effects of genetic susceptibility and aging. 
Therefore, we chose to give much lower oral doses of rotenone (5 mg/kg) over a longer period (twice weekly over 
Figure 6. Protein expression levels of mitochondrial respiratory Complex-I subunit (NDUFS4), TH and 
CoxIV in mouse striatum after 50-week oral rotenone administration. Mitochondrial NDUFS4 levels were 
specifically decreased in mutant mice after rotenone treatment, which was not seen in those similarly treated 
WT mice. There were no significant changes in both TH and CoxIV levels between WT and mutant mice after 
rotenone treatment. Data represents mean ± standard error of mean (SEM) from at least four mice per group; 
Statistical significance between groups was analyzed using Student’s unpaired t-test, **P < 0.01.
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half the mouse life span), which could induce apoptotic effects in the striatum of both treated WT and mutant 
mice without causing significant dopaminergic cell loss in the substantia nigra.
In our in vitro study, our mutant LRRK2 primary cortical neurons and mesencephalic DA neurons in cul-
ture were found to be more susceptible to rotenone toxicity in a dose-dependent manner (Figs 1c and d, 2b). 
Abnormalities in mitochondria morphology have previously been observed in striatum and cortex of mutant 
LRRK2 G2019S knockin mice52, and LRRK2 mutations can affect mitochondrial dynamics and function65. 
Since the nigrostriatal DA neurons are particularly vulnerable to energy deficiency because of their high 
energy-dependent autonomous pacemaker activity and vast arborization of presynaptic nerve terminals in the 
nigrostriatal network66,67, our findings of reduced cell viability suggested that mitochondria in mutant LRRK2 
neurons may be more vulnerable to rotenone-induced dysfunction than in WT.
Next, we explored whether such susceptibility would be evident in high energy-dependent DA nerve terminals 
in the striatum, thus adversely affecting DA uptake. Mitochondria in synaptic terminals have unique functional 
properties and are more prone to damage compared with those in the cell bodies68. Moreover, the efficiency of 
ATP production and oxidative stress levels in mitochondria are modulated by different degrees of uncoupling in 
response to various stresses69–74. Pre-synaptic dysfunction in striatum is one of the earliest abnormalities observed 
in patients at the early stages of PD75,76, and in experimental PD rodent models77,78. Previously, we had shown that 
DA uptake in striatal synaptosomes from both three and 18-month old mice did not have significant differences 
between WT and mutant LRRK2 knockin mice without administration of external stress51. Hence, we only used 
three month old mutant mouse synaptosomes to study the susceptibility of LRRK2 mutation to rotenone in syn-
aptosomal DA uptake because the use of 18-month old mice would have introduced an additional confounding 
factor of aging. In our ex vivo experiment, we found reduced DA uptake in striatal synaptosomes from mutant 
compared to WT mice after treatment with rotenone (Fig. 3a). We concurrently quantified, (i) CoxIV (mitochon-
drial cytochrome c oxidase subunit 4) levels to compare the amounts of mitochondria localized only in striatal 
nerve terminals (i.e. synaptosomes) between WT and mutant mice; (ii) SV2a for the amounts of synaptic vesicles; 
(iii) V-ATPase H for levels of vesicular proton pump; and (iv) synaptophysin levels in the synaptosomal lysates to 
normalize loading. Our findings showed that for the same amounts of isolated striatal synaptosomes, there were 
similar amounts of synaptic vesicles in mutant and WT samples but mutant synaptosomes had reduced protein 
Figure 7. Number of apoptotic nuclei in striatum and cortex of WT and LRRK2R1441G mutant mice after 
50-week oral rotenone administration. (a) Low magnification (X40) and (b,c) high magnification (X400) 
photomicrographs in striatal and cortical regions after TUNEL assay. TUNEL-positive nuclei (red arrow) were 
seen in striatum and cortex of both WT and mutant rotenone-treated mice. N = 3. Scale = 200 μ m (a) and 50 μm 
(b,c). (d) Quantification of TUNEL-positive cells in striatum and cortex (rectangular box). Statistical analysis 
of TUNEL-positive cell numbers in stained striatum and cortex regions showed that rotenone induced similar 
levels of apoptosis in both WT and mutant mice. Data represents mean ± standard error of mean (SEM) from 
three mice per group; Statistical significance between groups was analyzed using Student’s unpaired t-test, 
***P < 0.001.
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levels of both CoxIV (indicating lower amounts of mitochondria) and V-ATPase H (synaptic vesicle proton pump 
protein) (Fig. 3b). V-ATPase H acidifies synaptic vesicles in DA nerve terminals to maintain vesicular proton 
gradient essential for vesicular sequestration of DA via vesicular monoamine transporter-2 (VMAT2)79,80. This 
acidification process is highly energy-dependent and hence is particularly susceptible to any factor which reduces 
energy supply, e.g. rotenone toxicity79,80. Our findings indicate that the susceptibility to rotenone in mutant mice 
was likely due to reduced mitochondria and vesicle proton pump protein levels localized in their nerve terminals 
resulting in reduced DA uptake. Our current results are compatible with our previous findings where dopaminer-
gic synaptic function in young mutant LRRK2 mice was more vulnerable to stress induced by reserpine (VMAT2 
inhibitor)51.
Figure 8. Number of apoptotic nuclei in SNpc of WT and LRRK2R1441G mutant mice after 50-week oral 
rotenone administration. TUNEL-positive (green) TH-positive (red) dopaminergic neurons were counted in 
SNpc region of mice after rotenone treatment. (a) 50-week oral rotenone administration caused significantly 
greater number of TUNEL-positive DA neurons in both WT and mutant mice, as compared to their 
corresponding vehicle-treated groups. Scale = 150 μ m. (b) Quantitative results of TUNEL-positive DA neurons 
in SNpc. Statistical analysis showed that rotenone induced similar levels of apoptosis in both WT and mutant 
mice. Data represents mean ± standard error of mean (SEM) from three mice per group. Statistical significance 
between groups was analyzed using Student’s unpaired t-test, *P < 0.05.
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We further explored whether this vulnerability to rotenone was also found in vivo. Although there are previ-
ous reports involving rotenone injection in mouse models64,81,82, there were no similar studies using our unique 
oral rotenone treatment protocol for such a prolonged period of 50 weeks. Our preliminary dose finding experi-
ments using 1 mg/kg rotenone in young WT mice given orally up to 22 weeks did not show significant difference 
in the locomotor parameters between rotenone-treated and untreated mice (Supplementary Fig. 2). Hence, we 
used a twice weekly dosing protocol with 5 mg/kg oral doses of rotenone given over 50 weeks. Although this 
regime is laborious and time-consuming, it more accurately reflects long-term environmental exposure to a toxin. 
Furthermore, aging is inherent in our model because of the chronic nature of the toxic exposure, given over half 
the lifespan of the mice. Using three-way ANOVA, we analyzed using the cumulative locomotor data to deter-
mine whether each factor, namely aging, genotype and rotenone treatment, was associated with reduced locomo-
tor activity. Interestingly, the genotype (ie, LRRK2 mutation) alone was not associated with decreased locomotor 
activity in any of the three locomotor parameters. We took measures to minimize the effects of possible con-
founding factors by recording the activity at a similar time of day in the open-field tests, and observing the same 
batch of mice over 50 weeks of treatment. Furthermore, we only used male mice because we and others have pre-
viously shown the effects of estrogen on PD83, and effects of the estrus cycle on animal behavior84. Nevertheless, 
locomotor activity in individual mice is subject to large variations as would be expected with animal behavior. 
Hence, we analyzed the grouped cumulative locomotor parameters at 11 time points over the 50-week treatment 
period. Our vehicle-treated mutant mice appeared more active compared with vehicle-treated WT mice although 
the difference was not significant (Fig. 4b and d). However, rotenone treatment had a significant greater adverse 
impact on mutant mice in all three locomotor parameters compared to WT mice, to the extent that their cumula-
tive parameters in mutant mice fell below those of WT at all 11 time points (Fig. 4b and d).
After 50 weeks of rotenone exposure, the number of TH-positive neurons in mice treated with rotenone 
appeared similar to those treated with vehicle in both mutant and WT mice. This result is consistent with similar 
TH expression in total striatal lysates from WT and mutant mice treated with either vehicle or rotenone (Fig. 6). 
Although there was no significant difference in TH-positive cell numbers between WT and mutant brain SNpc 
region after rotenone treatment, levels of apoptosis as shown by number of TUNEL-positive nuclei in both stri-
atum and SNpc were significantly higher following rotenone compared to vehicle treatment, in both mutant and 
WT mice. This indicated that our chronic low oral doses of rotenone treatment was effective in inducing apop-
tosis in striatum, cortex, and SNpc without causing significant DA neuronal cell loss (Figs 7 and 8). Interestingly, 
although mitochondrial amounts in total striatal lysate as quantified by CoxIV levels were similar between mutant 
and WT mice after rotenone treatment, there was a significant and specific reduction in mitochondrial respiratory 
Complex-I component (NDUFS4) levels in striatum of mutant mice, which was not observed in rotenone-treated 
WT mice (Fig. 6b). NDUFS4 is a subunit of NADH dehydrogenase in the mitochondrial Complex-I assembly, 
and deletion of NDUFS4 reduced Complex-I function by approximately 50% in heart mitochondria85 and mouse 
embryonic fibroblasts86. A mouse model with midbrain-specific knockout of NDUFS4 showed impairment in DA 
homeostasis, and was more vulnerable to mitochondrial Complex-I toxin, MPTP87. Although further investiga-
tion is required to understand the detailed molecular mechanism of why there was specific reduction of NDUFS4 
level in our mutant LRRK2 mice, our current findings are compatible with the specific reduction of mitochondrial 
Complex-I in human PD brains, and can help to explain why our mutant LRRK2 primary neurons were more 
susceptible to rotenone-induced ATP deficiency and cell death.
Epidemiological studies have implicated environmental factors in the pathogenesis of sporadic PD88,89. 
Exposure to pesticides, such as rotenone and paraquat, can cause parkinsonism in human18,90. Acute high 
dose exposure to such pesticides, such as suicide attempts, has been reported to cause acute parkinsonism91,92. 
However, the vast majority of PD patients have no such acute exposure. Although it is difficult to demonstrate 
direct adverse effects of environmental toxins on humans in epidemiological studies because of various confound-
ing factors, humans are inevitably exposed to small doses of pesticides over their lifetime93,94. It is unclear what 
cumulative effects these pesticides pose in causing PD, especially in a genetically susceptible human. Therefore, 
we administered very low oral doses of rotenone regularly over half the lifespan of our mutant mice to reflect the 
lifelong exposure of environmental toxins in human.
In conclusion, our study showed that mutant LRRK2R1441G primary cortical and mesencephalic dopaminergic 
neurons were more susceptible to rotenone-induced toxicity than WT neurons. Lower DA uptake in striatal 
synaptosomes from mutant LRRK2 mice rotenone toxicity was associated with significantly less mitochondria 
and V-ATPase H protein localized in the nerve terminals compared with WT mice. The susceptibility of these 
mutant mice to rotenone-induced mitochondrial dysfunction was associated with more severe locomotor deficits 
in open-field tests. Although both mutant and WT mice had similar levels of DA cell number and apoptosis, the 
mutant mice had specific reduction in striatal NDUFS4 (mitochondrial Complex-I subunit) levels post-treatment, 
which was absent in the similarly treated WT mice. Our findings indicates that genetic susceptibility in the form 
of LRRK2 mutation conferred a significant vulnerability to long-term environmental toxicity as the mice aged 
over half their lifespan, involving reduced striatal mitochondrial Complex-I levels. Our unique experimental 
model of PD incorporates genetic effect, natural aging and prolonged oral environmental toxicity administered 
to mutant knockin LRRK2 mice over half their life span, with observable abnormalities that are compatible with 
those observed in human PD. This model is invaluable in further studies to explore the early pathogenic changes 
and disease modifying therapies of PD.
Materials and Methods
Animals. Homozygous mutant LRRK2 knockin mice carrying point mutation (c. 4321 C > G) of LRRK2 and 
their wildtype littermates were used for preparation of primary neuronal cultures and in vivo rotenone oral gav-
age experiments. Our mutant LRRK2R1441G knockin mice were previous described and published26,51. Similar to 
other LRRK2 knockin mouse models50,52, there was no overt phenotypic difference between WT and mutant 
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LRRK2R1441G mice even when these mice reached their old age of 18 months old without any external stress51. 
Our mutant LRRK2R1441G mice were back-crossed with wildtype C57BL/6 N mice for over eight generations, and 
maintained under such genetic background thereafter. All mice were maintained on a 12 hr light/dark cycle, with 
lights on at 7 AM in the Laboratory Animal Unit, University of Hong Kong, which is accredited by the Association 
for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). All experimental proto-
cols were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory 
Animals, and were approved by the Committee on the Use of Live Animals in Teaching and Research (CULATR) 
of the University of Hong Kong (CULATR#3452-14).
Rotenone oral gavage. Rotenone (Sigma #R8875) was dissolved in 4% carboxymethylcellulose (Sigma 
#C5678). Animals (30 week-old male mice) were given a 5 mg/kg rotenone dose or vehicle twice weekly for 50 
weeks. The rotenone solution and vehicle were administered by bolus oral gavage. Animals were weighed each 
week. Mice were subjected to open-field test every five weeks to detect the change of locomotor activity at 11 time 
points over 50 weeks.
Primary cell culture and treatments. Ventral mesencephalic and cortical tissues from 14–15 day 
embryos were excised, and were cut into small pieces in cold EBSS (Sigma) containing 100 units/ml of penicillin 
and 100 μ g/ml of streptomycin. Neuronal cells were dissociated by the Papain Dissociation System (Worthington 
Biochemical Corporation) according to manufacturer’s protocols. After dissociation, cells from the mesen-
cephalon and cortex were seeded on poly-L-lysine pre-coated coverslips (3 × 106 cells/well) or 24-well plates 
(0.5 × 106 cells/well) respectively.
Mesencephalic neurons were cultured in Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 
20% FBS at 37 °C in an atmosphere of 5% CO2/95% air. The medium was changed on the 2nd day in vitro. On the 
4th and 6th days in vitro half of the medium was replaced with serum-free DMEM containing 0.02 ml/ml B27 
(Gibco). AraC (5 μ M; Sigma) was added from 4th day in vitro. The mesencephalic neurons was treated with rote-
none (5 and 10 nM) or vehicle from 7th day in vitro for 48 hr, then fixed with 4% paraformaldehyde (PFA) for TH 
immunocytochemistry staining.
Cortical cells were cultured in neural basal medium (Gibco) with 2% B27 and 5% FBS at 37 °C in an atmos-
phere. On 2th DIV, medium was replaced with 5 μ M AraC serum-free medium. Half of the medium was replaced 
with serum-free medium twice per week. Cortical neurons on the 8th day in vitro were treated with either vehicle 
or rotenone (10, 25, 50 and 100 nM) for 6 hr, then assayed for ATP content and for cell viability or survival.
MTT cell viability assay. Cortical neurons in 24-well plates were added 3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyltetrazolium bromide (MTT) solution to achieve final concentration of 0.5 mg/ml and a final volume 
of 300 μ l/well. After this the plate was incubated at 37 °C for 1 hr. Formazan crystals, which developed inside 
each well, were dissolved by addition of DMSO (300 μ l) giving a purple solution. Then the purple solution was 
transferred to 96-well plate 100 μ l/well, and the intensity of this was determined by assaying absorbance at 570 nm 
using a CLARIOstar microplate reader (BMG LABTECH). Cell viability was regarded as directly related to 
absorbance. The experiments were repeated three times in triplicate for each experiment.
ATP assay. ATPlite™ Luminescence Assay System (PerkinElmer) was used to measure the intracellular ATP 
level according to the manufacturer’s protocol. Assay samples were transferred to wells of F96 MicroWell™ White 
Polystyrene Plates (Nunc). The luminescence, which represents the amount of ATP present in each sample, was 
measured by CLARIOstar microplate reader. The experiments were repeated three times in triplicate for each 
experiment.
Synaptosomal [3H]-dopamine uptake assay. The synaptosomal [3H]-dopamine uptake was assayed 
as previously described51. Briefly, synaptosomes from mice striatum were isolated. To test the effect of rotenone, 
synaptosomes and rotenone (100 nM, 1000 nM) or vehicle were incubated in Krebs–Ringer buffer (120 mM 
NaCl; 4.8 mM KCl; 1.3 mM CaCl2; 1.2 mM MgSO4; 1.2 mM KH2PO4; 25 mM NaHCO3; 6 mM glucose; pH 7.6) 
with 0.1 μ M [3H]-dopamine for 5 min at 37 °C. Dopamine uptake was stopped by addition of cold Krebs–Ringer 
buffer (200 μ l); the reaction solution was filter by a UniFilter®-96 GF/C filter, after washing and drying; [3H] 
Radioactivity (count per minute, cpm) was measured using a TopCount® NXTTM microplate scintillation & 
luminescence counter (Packard). Non-specific uptake was determined in the presence of 10 μ M nomifensine 
(DAT inhibitor). Specific [3H]-dopamine uptake was calculated as the difference between [3H] radioactivity in 
tested sample and paired negative control. Each treatment group was run in duplicate.
Histology. Mice under anesthesia were perfused with cold PBS followed by 4% PFA. Whole brain was 
removed and post-fixed in 4% PFA at 4 °C overnight. After dehydration, clearing, paraffin infiltration and embed-
ding, the midbrain (including substantia nigra) and striatum regions were sectioned coronally at 8 μ m thickness.
Immunohistochemistry. Paraffin tissue sections after antigen retrieval or cell cultures on coverslips were 
incubated with anti-TH antibody (1:500, Millipore #AB318) to determine the number of dopaminergic cells. 
Briefly, samples were incubated with primary antibody at 4 °C overnight in blocking TBS buffer containing 2% 
normal serum and 5% BSA. Samples were exposed to secondary antibody conjugated to HRP (Dako) for 1 hr at 
room temperature, and then HRP’s chromogenic substrate DAB (Dako) added. Color development was moni-
tored and photographed under light microscope. Stained coronal sections and primary cells on coverslips were 
dehydrated, cleared by xylene, and mounted with Richard-Allan Scientific™ Mounting Medium (ThermoFisher). 
Four consecutive sections taken from three individual mice in each treatment group were used to quantify the 
average total number of dopaminergic neurons in SNpc region. Optical intensity after DAB staining of tyrosine 
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hydroxylase in striatum was measured by ImageJ software (http://rsbweb.nih.gov/ij/plugins/track/track.html). 
Dopaminergic neurons on the coverslips were counted under blinded conditions by two independent observers. 
Each cell culture treatment was carried out in triplicate with a minimum of three experiments.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Paraffin tissue 
sections after antigen retrieval were assessed for the level of apoptosis using the TUNEL assay (in situ cell death 
detection kit, Roche) following the manufacturer’s protocol. Sections were incubated in 37 °C in dark for 1 hr, then 
washed 3 times in PBS. For DAB-stained TUNEL assay in cortex and striatum, the resultant stained slides were 
dehydrated, cleared by xylene, and mounted with Richard-Allan Scientific™ Mounting Medium (ThermoFisher). 
For immunofluorescent TUNEL assay in substantia nigra, the stained slides were incubated in 0.1% Sudan Black 
B before mounted with ProLong® Diamond Antifade Mountant (ThermoFisher). Random images were acquired 
from four consecutive sections taken from three individual mice in each group. Four randomly chosen regions 
in each photomicrograph were used to quantify the average number of TUNEL-positive cells for striatum and 
cortex region, whereas TUNEL-positive dopaminergic neurons in SNpc were counted under blinded conditions 
by two independent observers.
Locomotor activity test. Locomotor activity of mice was monitored using open field tests as described by51. 
The mice were kept in the experimental room for 3 days before testing. The mice moved freely in a plastic arena 
(26 × 26 × 40 cm), and were tracked for 1 hr using the EthoVision 3.0 system (Noldus Information Technology) 
at a similar time of day. Movement duration (seconds), distance moved (cm), rearing frequency (number of times 
standing on hind legs) of each mouse over 1 hr was recorded at 11 points over 50 weeks.
Immunoblotting. Mouse striatum was dissected and homogenized in cold lysis buffer (Cell signaling) with 
protease inhibitor cocktail (Roche). Protein lysates were incubated on ice for 20 min and clarified by centrifuga-
tion at 4 °C for 15 min at 14,000 rpm. Protein concentration was determined by the Bradford assay, and stored at 
− 80 °C. Equal amounts of protein were electrophoresed in 10%, 12 and 15% SDS-polyacrylamide gels at 100 volts 
for 1.5 to 2 hr and electro-transferred to nitrocellulose membranes. Membranes blot was probed with primary 
antibody, and followed by HRP-conjugated secondary antibodies (DAKO). Immunoblot results were visualized 
on X-ray film using Amersham ECL Western Blotting Detection Reagent (GE Lifesciences). Intensity of the vari-
ous protein bands was quantified using ImageJ software (http://rsbweb.nih.gov/ij/plugins/track/track.html). COX 
IV (1:2000, Abcam #ab16056, 16 kD), NDUSF4 (1:500, Santa-Cruz #sc-100567, 18 kD), TH (1:2000, Millipore 
#MAB318, 58 kD), Actin (1:500, Santa-Cruz #sc-1615, 43 kD), Synaptophysin (1:2000, Cell Signaling #D35E4, 
38 kD), V-ATPase (1:1000, ThermoFisher #PA5-22134, 55 kD), SV2a (1:1000, Santa-Cruz #sc-11936, 93 kD) were 
the primary antibodies used. Mice (4 to 6 mice) were used to detect the TH and mitochondria protein levels in 
each group. Six mice were used to detect the mitochondria and V-ATPase levels in striatal synaptosomes.
Statistical analysis. Data are expressed as mean ± standard error mean (SEM). Student’s t-test (Prism 
software package, GraphPad Software Inc.) was used to compare levels of protein expression; one-way ANOVA 
(Prism software package, GraphPad Software Inc.) was used to compare DA neuron viability; Student’s t-test and 
three-way ANOVA in the SPSS package (IBM) was used to analyze the locomotor activity in the open-field tests. 
For the three-way ANOVA, the raw and cumulative data (from 11 time points over 50 weeks) from the locomo-
tor activity parameters (distance moved, movement duration and rearing frequency) were analyzed separately. 
Differences between groups were considered significant at p < 0.05.
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